首页> 美国卫生研究院文献>Springer Open Choice >Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease

【2h】

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease

机译：Paricalcitol对3至5期慢性肾脏病患儿的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundElevated intact parathyroid hormone (iPTH) levels can contribute to morbidity and mortality in children with chronic kidney disease (CKD). We evaluated the pharmacokinetics, efficacy, and safety of oral paricalcitol in reducing iPTH levels in children with stages 3–5 CKD.

机译：背景完整的甲状旁腺激素（iPTH）水平升高可导致慢性肾脏病（CKD）儿童的发病率和死亡率。我们评估了口服帕可三醇在降低CKD 3-5岁儿童中iPTH水平方面的药代动力学，疗效和安全性。

著录项

期刊名称 Springer Open Choice
作者
Nicholas J. A. Webb; Gary Lerner; Bradley A. Warady; Katherine M. Dell; Larry A. Greenbaum; Gema Ariceta; Bernd Hoppe; Peter Linde; Ho-Jin Lee; Ann Eldred; Matthew B. Dufek;
展开▼
作者单位

展开▼
年(卷),期 -1(32),7
年度 -1
页码 1221–1232
总页数 12
原文格式 PDF
正文语种
中图分类外科学 ;
关键词
Secondary hyperparathyroidism Paricalcitol Chronic kidney disease–mineral and bone disorder Pediatric Hypercalcemia;

机译：继发性甲状旁腺功能亢进症;Paricalcitol;慢性肾脏疾病-矿物质和骨疾病;小儿;高钙血症;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease [J] . Webb Nicholas J. A., Lerner Gary, Warady Bradley A., Pediatric nephrology: journal of the International Pediatric Nephrology Association . 2017 ,第7期

机译：宿享苏氏酶在3至5次慢性肾病儿童中的疗效和安全性
2. CLINICAL TRAIL SIMULATIONS OF THE EXTRAPOLATED PHARMACOKINETICS, SAFETY AND EFFICACY OF PARICALCITOL IN CHILDREN 2-9 YEARS OF AGE WITH CHRONIC KIDNEY DISEASE. [J] . Stodtmann S., Mostafa N. M., Dufek M. B. Clinical Pharmacology and Therapeutics . 2018 ,第Suppla1期

机译：慢性肾病2-9岁儿童外推药代动力学，外推药代动力学，安全性和疗效模拟。
3. CLINICAL TRAIL SIMULATIONS OF THE EXTRAPOLATED PHARMACOKINETICS, SAFETY AND EFFICACY OF PARICALCITOL IN CHILDREN 2-9 YEARS OF AGE WITH CHRONIC KIDNEY DISEASE. [J] . Stodtmann S., Mostafa N. M., Dufek M. B. Clinical Pharmacology and Therapeutics . 2018 ,第Suppla1期

机译：慢性肾病2-9岁儿童外推药代动力学，外推药代动力学，安全性和疗效模拟。
4. The Natural History of Chronic Kidney Disease Revisited-A 72-Month Mayo Health System Hypertension Clinic Practice-Based Research Network Prospective Report on End-Stage Renal Disease and Death Rates in 100 High-Risk Chronic Kidney Disease Patients: A Call for Circumspection [C] . Macaulay A.C. Onuigbo Conference on Peritoneal Dialysis . 2009

机译：慢性肾病的自然历史重新审议-A 72个月的MASO卫生系统高血压诊所的研究网络网络前期肾病和死亡率100个高危慢性肾病患者的死亡率：一个呼吁守则
5. The effect of paricalcitol on proteinuria in non-dialysis chronic kidney disease patients [D] . Hojs, Nina 2015

机译：蛋白酸对非透析慢性肾病患者蛋白尿的影响
6. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease [O] . Tianzhao Han, Gong Rong, Dayong Quan, 2006

机译：荟萃分析：帕立骨化醇治疗慢性肾脏病继发性甲状旁腺功能亢进症和蛋白尿的疗效和安全性
7. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease [O] . 2017

机译：帕立骨化醇对3至5期慢性肾脏病患儿的疗效和安全性

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease

摘要

著录项

相似文献

相关主题

期刊订阅